Benitec Biopharma (BNTC) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.8 million.
- Benitec Biopharma's Income towards Parent Company fell 90.10% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 78.26%. This contributed to the annual value of -$38.5 million for FY2025, which is 78.26% down from last year.
- Latest data reveals that Benitec Biopharma reported Income towards Parent Company of -$8.8 million as of Q2 2025, which was up 39.37% from -$14.5 million recorded in Q1 2025.
- In the past 5 years, Benitec Biopharma's Income towards Parent Company ranged from a high of -$3.5 million in Q1 2022 and a low of -$14.5 million during Q1 2025.
- In the last 3 years, Benitec Biopharma's Income towards Parent Company had a median value of -$5.5 million in 2023 and averaged -$6.9 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first rose by 11.79% in 2024, then plummeted by 250.11% in 2025.
- Quarterly analysis of 5 years shows Benitec Biopharma's Income towards Parent Company stood at -$4.8 million in 2021, then dropped by 15.95% to -$5.6 million in 2022, then declined by 23.38% to -$6.9 million in 2023, then crashed by 43.98% to -$10.0 million in 2024, then tumbled by 90.10% to -$8.8 million in 2025.
- Its last three reported values are -$8.8 million in Q2 2025, -$14.5 million for Q1 2025, and -$10.0 million during Q4 2024.